2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2915

The Utility of Lupus Serology in Predicting Outcomes of Renal Transplantation in Lupus Patients: Systematic Review and Analysis of a Large Lupus Cohort
Abstract Number: 2916

Analysis of Risk Factors of the Progression to Chronic Kidney Disease and Comorbidities in Lupus Nephritis
Abstract Number: 2917

Combined Proliferative and Membranous Lupus Nephritis: Is the Prognosis Really Poor?
Abstract Number: 2918

Do Patients with Lupus Nephritis Who Achieve Complete Proteinuria Recovery at 2 Years Have Better Long Term Outcomes Compared to Patients with Partial Proteinuria Recovery?
Abstract Number: 2919

Effect of Thrombotic Microangiopathy on Clinical Outcomes in LUPUS Nephritis
Abstract Number: 2920

Time to Recovery of Individual Lupus Manifestations on Standard of Care Treatment
Abstract Number: 2921

Lupus Nephritis: An Exploration of Management Style
Abstract Number: 2922

HLA-Specific Antibody Profile in Renal Transplant Patients with Systemic LUPUS Erythematosus
Abstract Number: 2923

The Effects of Disease Activity and Mood Disorders on Cognitive Function in Systemic Lupus Erythematosus
Abstract Number: 2924

Determinants of Damage in an SLE Cohort: Real World Data
Abstract Number: 2925

Factors Associated with Early Damage Accrual in Patients with Systemic Lupus Erythematosus: 12-Month Preliminary Results from the Inception Cohort of the Multicenter Early Lupus Project
Abstract Number: 2926

Cytochrome P450 Polymorphisms on Blood Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus
Abstract Number: 2927

Disease Activity Patterns over Time in Patients with SLE – a Retrospective Descriptive Analysis of the Hopkins Lupus Cohort
Abstract Number: 2928

Persistent Disease Activity over Time in a Large Canadian Cohort of Prevalent Lupus Patients
Abstract Number: 2929

Diet and Glucocorticoid Treatment in Patients with SLE

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].